Full text is available at the source.
Abstract
Mesenchymal stem cells (MSCs) may have potential as novel treatments for diabetic kidney disease (DKD).
- Diabetic kidney disease is a major complication of diabetes and a leading cause of end-stage renal disease.
- MSCs exhibit anti-inflammatory, antioxidant, antifibrotic, and regenerative properties.
- Current MSC-based therapies for DKD are still in early clinical research stages.
- Key signaling pathways involved in MSC renal protection include Wnt/β-catenin, PI3K/Akt/mTOR, VEGF, TGF-β1/Smad, and Nrf2.
- Other signaling pathways that may also impact MSC effectiveness in DKD require further exploration.
Simplified